Evaluation of Biosimilars for Formulary Inclusion: Factors for Consideration by P&T Committees.
about
Evaluation of Biosimilars for Formulary Inclusion: Factors for Consideration by P&T Committees.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Evaluation of Biosimilars for ...... nsideration by P&T Committees.
@ast
Evaluation of Biosimilars for ...... nsideration by P&T Committees.
@en
type
label
Evaluation of Biosimilars for ...... nsideration by P&T Committees.
@ast
Evaluation of Biosimilars for ...... nsideration by P&T Committees.
@en
prefLabel
Evaluation of Biosimilars for ...... nsideration by P&T Committees.
@ast
Evaluation of Biosimilars for ...... nsideration by P&T Committees.
@en
P2860
P1476
Evaluation of Biosimilars for ...... nsideration by P&T Committees.
@en
P2093
C Lee Ventola
P2860
P304
P577
2015-10-01T00:00:00Z